All News
Steroid injections worsen knee arthritis
d
EurekAlert!
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
Read Article
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
Mayo LUMEN study looked at SLE nephritis incidence betw 1976 -2018, & showed that LN increased over past 4 decades. LN patients have poor outcomes w/ higer rates of ESRD & mortality rates (SMR 6.33); @10 yr survival =70% & 13% ESRD https://t.co/QDDTORSgyZ https://t.co/89ldzxhuMk
Links:
Dr. John Cush RheumNow ( View Tweet)
Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA
Early diagnosis of AxSpA remains a challenge. Strategies to identify patients with suspected inflammatory back pain in the general population is critical.
https://t.co/LsKOOHDOJI https://t.co/NARG61vBSn
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual inhibition of IL17A and IL17F in AxSpA
https://t.co/OvzQnYw7dH https://t.co/qkCsyBofDJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Do different genders experience PsA differently?
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.
Dr. Petryna ( @DrPetryna) weighs in. #ACR22
https://t.co/nPHf2fR6gQ https://t.co/CcO2gwgh3Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Advancing Telehealth in Rheumatology #ACR22
https://t.co/TZL2ZHVTax https://t.co/4Z5Sbvpo23
Links:
Dr. John Cush RheumNow ( View Tweet)
mTORC1 as a Driver of Inflammation in sJIA Connecting Pathogens of sJIA and MAS
Dr. Olga Petryna discusses Abstract 0004 presented at #ACR22
Abstract 0004: mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
https://t.co/XLbchHGG6w https://t.co/h5KArPYrPZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Can you use the BASDAI in Pregnancy?
Dr. Eric Dein ( @ericdeinmd) discusses abstract 0374 presented at #ACR22 Convergence in Philadelphia, PA. Abstract 0374: The BASDAI Index During Pregnancy.
https://t.co/UB8ZGyQ6mz https://t.co/tkr6cOIMD9
Links:
Dr. John Cush RheumNow ( View Tweet)
Vaccine Efficacy in Patients with Seronegative SpA
Vaccine efficacy remains an important topic at #ACR22 given the ongoing COVID-19 health crisis, current influenza season, and recently published 2022 ACR guidelines.
https://t.co/2PHrJYV8Om
Written by Dr. Sims ( @DrCassySims) https://t.co/hUFnPIDzUU
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we accurately capture disease activity in pregnant patients with AS?
Dr. Aurelie Najm ( @AurelieRheumo) discusses Abstract 0374. #ACR22
https://t.co/oafV1BP91X https://t.co/wMelZm5iOj
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar
Dr. Julian Segan ( @JulianSegan) discusses Abstract 1425 at #ACR22
Abstract 1425: Treatment Persistence and Switching Patterns of AMGEVITA® in German Patients with RD
https://t.co/MpNnrqYxGJ https://t.co/Sfi1kxOXLX
Links:
Dr. John Cush RheumNow ( View Tweet)
Fat and bone are never alone: osteoporotic fracture in RA
Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
https://t.co/4IrdQBq1z2 https://t.co/2HySVG1SGY
Links:
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts #ACR22 - SpA Part3
-Opioids and Health Care Utilization in PsA and AS
-Reproductive health in a post-Roe world
-SpA: Novel Therapies, Diagnostic Dilemmas and Depression
-Tapering TNFi in nonradiographic AxSpA
and more
https://t.co/hXPlQaxPWs https://t.co/2SRYS6EOr7
Links:
Dr. John Cush RheumNow ( View Tweet)
How Underweight Women Can Reduce Hip Fracture Risk
https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS
Links:
Dr. John Cush RheumNow ( View Tweet)
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/cpbDnkfUIS https://t.co/xct8dACBAY
Links:
Dr. John Cush RheumNow ( View Tweet)
RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evobrutinib(861) or placebo(271) for ~ 6 mos. No diff in TEAEs or EAIR , 2 deaths (SLE), SIE 2-3/100PY https://t.co/4HOTKuCAUi https://t.co/u7KSD6RN4q
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/ufYcnuMI2r https://t.co/cOPIUpwpHf
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/nuq8Ioralk https://t.co/djwlVsIk3b
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - SpA Part2
-Comorbidities in Ankylosing Spondylitis
-Early Diagnosis of AxSpA
-Fertility issues in SpA
-Gender in AxSpa
-Inadequate Dosing of HCQ Leads to Hospitalizations in SLE
-JAK inhibitors in RD
-Opioid use in PsA and SpA
https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4
Links:
Dr. John Cush RheumNow ( View Tweet)